Activation of the Wnt signaling pathway initiates the transformation of colorectal epithelial cells, although the transition to metastatic cancer requires angiogenesis. We have investigated the expression of the von Hippel-Lindau (VHL) tumor suppressor in the intestines from humans and mice. Here, we show that VHL expression is regulated by TCF4 and is restricted to the proliferative compartment at the bottom of intestinal crypts. Accordingly, VHL is completely absent from the proliferative intestinal pockets of Tcf4 À/À perinatal mice. We observed complementary staining of the hypoxia-inducible factor (HIF) 1a to VHL in normal intestinal epithelium as well as in all stages of colorectal cancer (CRC). To the best of our knowledge, this is the first report demonstrating the presence of nuclear HIF1a in normoxic healthy adult tissue. Although we observed upregulated levels of VHL in very early CRC lesions from sporadic and familial adenomatous polyposis patients -presumably due to activated Wnt signaling -a clear reduction of VHL expression is observed in later stages of CRC progression, coinciding with stabilization of HIF1a. As loss of VHL in later stages of CRC progression results in stabilization of HIF, these data provide evidence that selection for VHL downregulation provides a proangiogenic impulse for CRC progression.
Activation of the Wnt signaling pathway initiates the transformation of colorectal epithelial cells, although the transition to metastatic cancer requires angiogenesis. We have investigated the expression of the von Hippel-Lindau (VHL) tumor suppressor in the intestines from humans and mice. Here, we show that VHL expression is regulated by TCF4 and is restricted to the proliferative compartment at the bottom of intestinal crypts. Accordingly, VHL is completely absent from the proliferative intestinal pockets of Tcf4 À/À perinatal mice. We observed complementary staining of the hypoxia-inducible factor (HIF) 1a to VHL in normal intestinal epithelium as well as in all stages of colorectal cancer (CRC). To the best of our knowledge, this is the first report demonstrating the presence of nuclear HIF1a in normoxic healthy adult tissue. Although we observed upregulated levels of VHL in very early CRC lesions from sporadic and familial adenomatous polyposis patients -presumably due to activated Wnt signaling -a clear reduction of VHL expression is observed in later stages of CRC progression, coinciding with stabilization of HIF1a. As loss of VHL in later stages of CRC progression results in stabilization of HIF, these data provide evidence that selection for VHL downregulation provides a proangiogenic impulse for CRC progression. Keywords: von Hippel-Lindau; Wnt signaling; hypoxiainducible factor; colorectal cancer Greater than 90% of all colorectal cancers (CRCs) have an activating mutation of the canonical Wnt signaling pathway, ultimately leading to b-catenin/TCF4-mediated gene transcription (Giles et al., 2003) . However, to progress from an adenoma to a carcinoma, increased oxygen and nutrient demands must be met by the formation of new capillaries from pre-existing vasculature -referred to as the angiogenic switch (Folkman et al., 1989; Aotake et al., 1999) . Both preclinical and clinical evidence indicate that vascular endothelial growth factor (VEGF) plays an important role in the angiogenic switch of CRC. Several clinical trials with anti-VEGF approaches are underway both in the adjuvant and metastatic disease settings (Mayer, 2004) , underscoring the relevance of VEGF in CRC progression.
VEGF levels are regulated by the hypoxia-inducible factor 1 (HIF1). HIF1 is normally rapidly degraded in the presence of oxygen, a process that requires the von Hippel-Lindau (VHL) tumor suppressor. VHL specifically recognizes prolyl-hydroxylated HIFa (a modification requiring oxygen), thereby targeting it for ubiquitination and subsequent degradation by the proteasome (Cockman et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001) . Thus, biallelic inactivation of VHL leads to HIF1a stabilization and upregulation of HIF1 target genes, resulting in an inappropriate triggering of the hypoxic response under normal oxygen tension (Bluyssen et al., 2004; Maynard and Ohh, 2004) . Patients with VHL disease, an inherited autosomal dominant cyst and cancer syndrome, develop highly vascularized lesions and tumors secreting high levels of VEGF (Wizigmann-Voos et al., 1995; Los et al., 1997) . The observation that VEGF plays an important role in CRC progression together with reported VHL expression in colonic mucosa (Los et al., 1996) led us to investigate whether aberrant regulation of VHL contributes to the angiogenic switch in CRC.
We began by sequencing the entire open-reading frame of VHL in a number of CRC cell lines and found them all to be wild type despite variable expression levels (data not shown). One cell line in particular was found to express high levels of VHL: LS174T. Next, we used LS174T cells that were engineered to express dominantnegative TCF4 (dn-TCF4) under the control of a doxycycline-inducible promoter (dubbed L8). dn-TCF4 does not bind b-catenin and acts as a potent inhibitor of the endogenous b-catenin/TCF complexes present in CRC cell (van de Wetering et al., 2002) . To investigate the influence of Wnt signaling on VHL levels in these cells, we performed RT-PCR for VHL with RNA derived from L8 cells either at baseline or after stimulation with doxycycline for 16 h. As has been published previously (Batlle et al., 2002) , transcript levels of the well-characterized Wnt target tyrosine kinase receptor EphB2 were greatly diminished by treating this cell system with doxycycline ( Figure 1a) . Intriguingly, VHL transcript levels responded similarly ( Figure 1a) . As VHL inactivation results in increased VEGF transcription, we also performed RT-PCR for VEGF in the same experiment. VEGF levels increased 3.3-fold after treatment of L8 cells with doxycycline ( Figure 1a) , indicating an intact response to VHL downregulation. Doxycycline alone had no effect on VHL levels in LS174T cells stably transfected with empty vectors (not shown). HIF1a RNA levels mirrored the 18S cDNA input control (Figure 1a ), indicating that b-catenin/TCF4 signaling has little effect on HIF1a RNA levels. To verify the induction of dn-TCF4 in this , 2002) . Cells were induced for 24 h with doxycycline (dox; 1 mg/ml). RNA from cell lysates was extracted using RNAbee (Campro Scientific, Veenendaal, The Netherlands). cDNA was made using 2 mg of total RNA and reverse transcribed using Superscript Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and random hexamers. Gene-specific cDNA fragments were amplified by 25 cycles of PCR consisting of 1 min at 951C, 1 min at 551C and 2 min at 721C. PCR fragments were analysed by DNA gel electrophoresis. We used the following primers: VHL-Fw: 5 0 -gctaccgaggtcacctttgg, VHL-Rev: 5 0 -tgtgtcagccgctccaggtc; VEGF-Fw: 5 0 -cgaaaccatgaactttctctgc, VEGF-Rev: 5 0 -ccacttcgtgatgattctgc; EphB2-Fw: 5 0 -cgtgactgcagcagcatc, EphB2-Rev: 5 0 -cagtagagcttgatgggtac; HIF1a-Fw: 5 0 -gctgatttgtgaacccattcctc, HIF1a-Rev: 5 0 -agtttctgtgtcgttgctgc; 18S-Fw: 5 0 -agttggtggagcgatttgtc, 18S-Rev: 5 0 -tattgctcaatctcgggtgg. Lower two panels show Western blot (WB) analysis on 10% acrylamide gels of the protein expression levels of FLAG-tagged dn-TCF4 (M2 a-FLAG, 1:2500; Sigma) and the loading control b-actin (AC-15, 1:20 000; Abcam). Rabbit anti-mouse HRP (1:20 000; Pierce, Rockford, IL, USA) was used as secondary antibody after which enhanced chemiluminescence (Perkin-Elmer Life Sciences, Boston, MA, USA) was used for detection. Antibodies were diluted in PBS containing 5% dry skimmed milk and 0.1% Tween-20. All experiments were repeated three times independently. (b) Western blots of 293T cell lysates at baseline (À) or after 5 h treatment with 20 mM LiCl ( þ ; Sigma). Specific protein bands on the Western blots were visualized using supernatant from anti-VHL monoclonal hybridoma specifically recognizing the C-terminus of VHL (1B3B11) generated using a protocol we have preciously described (van Noort et al., 2002) . Hybridoma supernatant was diluted 1:5 in PBS containing 5% milk and 0.1% Tween-20. Top panel, VHL protein levels; middle panel, non-phosphorylated activated b-catenin (a-ABC, clone 8E7 hybridoma supernatant 1:5; Upstate) as a positive control for activated Wnt signaling; lower panel, loading control b-actin (AC-15, 1:20 000; Abcam). This figure shows a representative image of three independent experiments with similar outcome. (c) Western blot of VHL protein levels in 293T cell lysates after 16 h cultured with conditioned medium from either mouse L fibroblasts transfected with an empty plasmid (À) or with a plasmid expressing soluble Wnt3A ligand ( þ ) prepared as described (Shibamoto et al., 1998) . Middle panel shows the positive control for activated Wnt signaling: non-phosphorylated activated b-catenin (ABC). Lower panel shows the loading control actin. This figure shows a representative image of three independent experiments with similar outcome. (d) The transcriptional activity of HIF1a is reduced by b-catenin. To generate the HRE-luciferase reporter construct (HRE-Luc, filled bars), we used the following wild-type HRE oligonucleotide (W18) of the 3 0 -enhancer of the human erythropoietin gene (Wang and Semenza, 1993) in triplicate in front of a minimal TK promotor and the Luciferase gene in the vector pBlLuc: C(TACGTGCT)GC(TACGTGCT)GC(TACGTGCT)G (where the HRE is in parentheses and the core bases essential for HIF binding are underlined). The vector pBlLuc is derived from pBlCat2 (Luckow and Schutz, 1987) , in which the Cat gene has been replaced by Luciferase out of pTopFlash (Korinek et al., 1997) . As a negative control, a similar construct (Mut-Luc, empty bars) with the M28 fragment (Wang and Semenza, 1993) was constructed in which three altered nucleotides completely abrogate HIF binding: CTCAATGCTGCTCAATGCTGCTCAATGCTG-3 0 (where the mutated core bases are underlined). 293T cells were plated 18 h before transfection by Fugene6 (Roche, Basel, Switzerland) according to the manufacturer's instructions. The following plasmids were transfected into 293T cells: 50 ng HRE-Luc or Mut-Luc in combination with 5 ng of the Renilla internal control CMV-pRNL (Promega, Madison, WI, USA), and 100 ng wild-type HIF1a (120 kDa), Vsv-tagged VHL (30 kDa) and/or FLAG-tagged constitutively active S33 b-catenin (94 kDa). Cells were treated 5 h with 20 mM LiCl as indicated. The total amount of DNA transfected was adjusted to 500 ng with pcDNA 3 (mock). Luciferase activities were measured 24-36 h after transfection using the DUAL luciferase system according to the manufacturer's protocol (Promega, Madison, WI, USA). Experiments were performed in duplicate and repeated at three independent time points. Bars show the standard error of the mean. Western blots in the right panel show construct expression and HIF1a levels. Antibodies used: a-FLAG (1:2500, M2; Sigma), a-HIF1a (1:500; BD Transduction Laboratories) and a-Vsv (P4D5, hybridoma supernatant 1:5). In parallel experiments, cDNA was generated; HIF1a and 18S transcript levels were amplified as described in (a). experiment, we simultaneously prepared L8 protein lysates and tested the expression of the FLAG-tagged dn-TCF4 construct by Western blot. Anti-FLAG staining shows a specific band at the expected height of 85 kDa only in the cells induced with doxycycline ( Figure 1a) . b-Actin staining verifies equal protein loading (Figure 1a) . We concluded from this experiment that blocking b-catenin/TCF4 affects VHL transcript levels in a manner suggestive of a Wnt signaling target. We subsequently performed experiments to test whether VHL levels could respond to upstream Wnt signaling. LiCl mimics Wnt signaling by inhibiting GSK3b, thus allowing non-phosphorylated b-catenin levels to accumulate (Stambolic et al., 1996) . Stimulation with LiCl markedly increased endogenous VHL levels in 293T cells (Figure 1b) , in addition to non-phosphorylated bcatenin (Figure 1b) . To substantiate this finding, we determined whether soluble Wnt3a protein could also regulate VHL levels. To this end, we stimulated 293T cells overnight with conditioned medium derived from mouse fibroblast L cells secreting Wnt3a (Shibamoto et al., 1998) . Accumulation of non-phosphorylated bcatenin ( Figure 1c ) served again as control for the activation of the pathway. Consistent with the previous data, Wnt3a stimulation also resulted in VHL accumulation (Figure 1c) , suggesting that VHL is downstream of Wnt signaling.
Wnt signaling regulates VEGF through VHL and HIF1a: To investigate the direct influence of b-catenin/ TCF on HIF activity, we performed HIF1a reporter assays. We generated luciferase reporter constructs with three tandem hypoxia response elements (HREs) derived from the promoter of the erythropoietin gene (HRE-Luc) or three HREs with three nucleotide mismatches (Mut-Luc). 293T cells were co-transfected with either the HRE-Luc or the Mut-Luc reporter plasmids and with the combinations of empty vector (mock), HIF1a, VHL and constitutively active S33 bcatenin and/or were treated with LiCl as indicated in Figure 1d . All samples were co-transfected with Renilla as a transfection efficiency control. Background levels of HIF1a activity in 293T cells decreased somewhat when treated with LiCl, and increased approximately fourfold upon transfection of HIF1a. As expected, co-transfection of VHL with HIF1a greatly reduced HIF1a activity, which was mirrored by co-transfecting S33 bcatenin or by treating HIF1a-transfected cells with LiCl. Western blots confirmed reduced HIF1a protein stability when co-transfected with either VHL or b-catenin; however, HIF1a RNA levels are not affected (Figure 1d , right panels). Mut-Luc background levels remained low, indicating an HIF1a-specific effect. These data suggest that upregulation of VHL by b-catenin/TCF reduces HIF1a activity.
VHL is a physiological target of Wnt signaling: To determine whether VHL also demonstrates characteristics of a Wnt target in physiological circumstances, we performed immunohistochemical analysis of VHL staining in normal adult intestine. At the bottom of intestinal crypts, stem cells give rise to a transient population of undifferentiated cells that vigorously proliferate as they migrate towards the lumen of the intestine. Epithelial cells at the bottom of crypts, close to the putative Wnt source, accumulate nuclear b-catenin and accordingly show high levels of proteins positively regulated by Wnt (van de Wetering et al., 2002) . Consistent with the in vitro data, VHL expression is limited to cells at the bottom of crypts and tapers off along the crypt-villus axis (Figure 2a) . Interestingly, expression of HIF1a inversely correlates with that of VHL; it is absent at the presumptive Wnt source at the bottom of the crypt, low at the intermediate positions in the crypt and peaks at the luminal surface epithelium. To the best of our knowledge, this is the first documentation of nuclear HIF expression in normoxic healthy adult tissue. This localization supports data that a HIF1a target gene -the intestinal trefoil factor -might be essential at the intestinal lumen for barrier formation and injury repair in intestinal mucosa (Furuta et al., 2001) . Furthermore, HIF signaling has been implicated in maintaining colonic integrity in a colitis model (Karhausen et al., 2004) . Thus, while HIF1a seems to play a protective role in the intestinal epithelium in genetic models, localization of HIF1a expression in the intestine has remained elusive.
The distribution of VHL and HIF1a in the gut prompted us to examine the intestines of mice deficient for Tcf4. In the late fetal small intestine, Tcf4 expression is mainly confined to the intervillus pockets, the prospective crypts of Lieberku¨hn (Korinek et al., 1998) . To study whether VHL expression in the intestine is dependent on TCF4, we determined the expression pattern of VHL in the small intestine of E18 Tcf4 mutant embryos ( Figure 2b) ; older mice could not be examined because these mice die (Korinek et al., 1998) . In the Tcf4 þ /À control mice, VHL expression was readily detectable in the pseudostratified intervillous epithelium. In sharp contrast, the intestinal epithelium of Tcf4 À/À mice did not show any VHL staining (Figure 2b) . Unfortunately, there are no available antibodies that recognize murine HIF1a, thus we were unable to examine the expression pattern of HIF1a in a Tcf4 We next studied the expression of VHL in the intestinal mucosa of patients with familial adenomatous polyposis (FAP), an uncommon cancer syndrome associated with germline-activating mutations of Wnt signaling. In all atypical crypt foci and polyps examined from 12 FAP patients, VHL was highly expressed (Figure 2c and d) . Nuclear b-catenin was observed in all polyp and adenoma tissues (not shown). HIF1a could not be detected in these early lesions (Figure 2d ). We concluded that both legitimate and illegitimate activation of Wnt signaling stimulate VHL expression in intestinal mucosa.
VHL in sporadic CRC:
We performed immunohistochemical analyses of 19 spontaneous CRCs of various pathological grades. Heterogeneous expression of VHL and HIF was observed. In the early adenomatous lesions, clonal loss of VHL could be observed, suggestive of a selective mechanism (Figure 3a and b) . In some adenomas loss of VHL, expression was quite striking, and correlated perfectly with HIF1a stabilization (Figure 3a) . However, examining CRCs further along the adenoma-carcinoma sequence, we never detected VHL expression in late adenomas and carcinomas (n ¼ 14), despite the increased levels of cytoplasmic and nuclear b-catenin in the tumor tissue (Figure 4a and b) . Relatively normal adjacent tissue expressed normal levels of VHL. Loss of VHL expression coincided with the accumulation of HIF1a expression. In 9/19 samples, the nuclear HIF1a staining was prominent in perinecrotic regions (not shown), whereas in the remaining 10 samples, it generally localized to well-vascularized regions. In short, whereas nuclear b-catenin continues to accumulate during adenoma-carcinoma progression, at some point VHL levels become uncoupled from the Wnt pathway, perhaps through selection for clones downregulating VHL either by promoter methylation, by chromosome loss, or by gene mutation. Furthermore, the presence of stabilized nuclear HIF1a in welloxygenated areas (i.e. adjacent to blood vessels) suggests a hypoxia-independent mechanism -such as VHL inactivation, for HIF1a stabilization; whether the pattern of HIF1a staining in CRCs correlates with patient prognosis, as has been recently been established for breast cancer (Vleugel et al., 2005) , is yet to be determined.
A number of studies support a role for VHL inactivation/HIF1a stabilization in the progression of Figure 2 VHL is an in vivo target of Wnt signaling. (a) Immunohistochemical analysis of VHL and HIF1a in the small intestine reveals that VHL expression is restricted to the cells in the intervillus regions (left), whereas HIF1a (middle) is expressed in a complementary pattern by the adjacent cells in the villus. Samples were obtained immediately after excision biopsy procedures from patients treated at the University Medical Center Utrecht, The Netherlands and fixed in neutral 4% buffered formaldehyde at 41C for 24 h. Individual segments were embedded in paraffin and sectioned (4-5 mm). Paraffin sections were mounted on silane-coated slides and baked overnight at 571C. Following dewaxing and hydration, sections were pretreated with peroxidase blocking buffer (1.5% H 2 O 2 in methanol) for 20 min at room temperature. Antigen retrieval was performed by boiling samples in 10 mM sodium citrate, pH 6.0. After 20 min the boiling pan was allowed to slowly cool down to room temperature. Incubation of a-VHL (Ig32, diluted 1:100l Transduction Labs/Pharmigen, Alphen aan den Rijn, The Netherlands) was performed in 10% normal goat serum in PBS overnight at 41C. Powervision poly-HRP goat-anti-mouse IgG (Immunologic, Duiven, The Netherlands) was used as a secondary reagent. Stainings were developed using DAB (brown precipitate) and then counterstained with hematoxylin (blue nuclei) and mounted. To exclude cross-reactivity of a-VHL with other Wnt signaling targets, we pre-incubated this antibody for 30 min with 2.5 mg recombinant VHL, which completely abrogated all signal in the intestine (not shown). Anti-HIF1a immunohistochemistry was performed as we have described previously (Bos et al., 2001) CRC. Firstly, loss or alteration of the VHL locus on chromosome 3p is commonly associated with the progression and poor prognosis of CRC (Iniesta et al., 2000; Fujii et al., 2002; Goel et al., 2003) . Accordingly, while allelic loss of VHL has not been detected in intestinal early adenomas, 64% of carcinomas have been reported to harbor VHL deletions, indicating a role for VHL loss in later stages of tumor progression (Zhuang et al., 1996) . Another recent study sequenced VHL in 88 paraffin-embedded CRC specimens and found 10 (11%) point mutations (Kuwai et al., 2004) . A relationship between HIF levels, VEGF expression, tumor invasion, liver metastasis and microvessel density was recently demonstrated in CRC patients (Kuwai et al., 2003) . Almost 60% of archived CRC samples expressed HIF1a protein at a high level. These findings support the notion that HIF1a may play a role in angiogenesis and tumor progression via regulation of VEGF in human colorectal carcinoma. Another study reported nuclear HIF1a overexpression in 22/22 colon adenocarcinomas examined . Lastly, HIF1a overexpression has been implicated in colon carcinoma cell invasion (Krishnamachary et al., 2003) .
In apparent contrast to our data, one study showed that b-catenin signaling upregulated VEGF-A mRNA and protein levels by 250-300% (Easwaran et al., 2003) . The authors postulated that the upregulation of VEGF was mediated by a direct binding of b-catenin/TCF4 to consensus binding sites within the gene promoter of VEGF. However, our data support the role of HIF1a in VEGF regulation in CRC cells reported by Semenza and colleagues (Fukuda et al., 2003) . These two mechanisms of VEGF regulation are not mutually exclusive. Easwaran et al. used different colorectal cell lines than we did, with unknown VHL levels or HIF1a transcriptional activity at the VEGF promoter. Morphological and gene expression studies suggest that the LS174T cells we used are typical for an early CRC with no known secondary mutations (van de Wetering et al., 2002) ; consistent with our hypothesis, this cell line exhibits high endogenous VHL levels and low HIF1a activity. Easwaran et al. did not examine the effects of bcatenin/TCF4 on HIF1a activity at the VEGF promoter. We are therefore unable to directly compare our results. Our system demonstrates that VHL is a target of Wnt signal in vitro and in vivo, and that turning off TCF4 function in modified LS174T colorectal cells leads to an increase in VEGF mRNA levels, presumably through HIF1a. Thus, while b-catenin/TCF4 might directly upregulate VEGF, it is unclear if this is true throughout the adenoma-carcinoma sequence, whether it affects all cell types, or how it can be influenced by HIF1a. If VEGF is directly regulated by b-catenin/TCF4 even in early lesions, our data in LS174T cells suggest that is effectively counterbalanced by simultaneous upregulation VHL, resulting in low VEGF levels ( Figure 1a) . We consider our data to be complementary to Easwaran et al.
The presence of nuclear HIF1a has been extensively associated with the advent of angiogenesis in many Advanced colorectal carcinomas uncouple VHL regulation from Wnt signaling. Sequential sections of two representative carcinomas (a and b, respectively) stained for b-catenin (upper panels), VHL (middle panels) and HIF1a (lower panels). Whereas b-catenin nuclear and cytoplasmic staining increases in the carcinoma tissue, VHL stains only the adjacent normal tissue, whereas nuclear HIF1a stains in a purely complementary manner to VHL. None of the patients with CRC had received any preoperative therapy. Samples for b-catenin staining were fixed in 10% neutral-buffered formalin for 12 h at 41C, and stained as described previously (van de Wetering et al., 2002). tumor settings (Carmeliet et al., 1998; Bos et al., 2001; Kuwai et al., 2003) . Thus, correlative data and biological plausibility support a role for VHL downregulation in the angiogenic switch in CRC progression. This hypothesis is supported by the wealth of data on the regulation of HIF1a and VEGF by VHL (reviewed by Maynard and Ohh, 2004) , in addition to our findings that decreased VHL levels in colorectal cells correlated with increased HIF1a and VEGF. As angiogenesis represents a powerful control point in tumor development, investigation of the physiological mechanisms underlying this process in CRC has direct relevance to the development of future therapeutics.
